Prognostic and clinicopathological value of systemic inflammation response index (SIRI) in patients with breast cancer: a meta-analysis

References

• Loibl S, Poortmans P, Morrow M, et al. Breast cancer. Lancet. 2021;397(10286):1–11. 2021/04/05. doi: 10.1016/s0140-6736(20)32381-3.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. 2021/02/05. doi: 10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300. 2019/01/23. doi: 10.1001/jama.2018.19323.
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867. doi: 10.1038/nature01322.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi: 10.1038/nature07205.
   PubMed Web of Science ®Google Scholar
• Sun W, Zhang L, Luo M, et al. Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: neutrophil-lymphocyte ratio and platelet-lymphocyte ratio. Head Neck. 2016;38 Suppl 1(S1):E1332–1340. 2015/09/13. doi: 10.1002/hed.24224.
   PubMedGoogle Scholar
• Chen T, Tang M, Zhou Y, et al. Pretreatment lymphocyte-to-monocyte ratio as a prognostic factor and influence on dose-effect in fractionated stereotactic radiotherapy for oligometastatic brain metastases in non-small cell lung cancer patients. Front Oncol. 2023;13:1216852. 2023/07/17. doi: 10.3389/fonc.2023.1216852.
   PubMed Web of Science ®Google Scholar
• van Wijk L, de Klein GW, Kanters MA, et al. The ultimate preoperative C-reactive protein-to-albumin ratio is a prognostic factor for survival after pancreatic cancer resection. Eur J Med Res. 2020;25(1):46. 2020/10/09. doi: 10.1186/s40001-020-00444-z.
   PubMed Web of Science ®Google Scholar
• Xu S, Cao S, Geng J, et al. High prognostic nutritional index (PNI) as a positive prognostic indicator for non-small cell lung cancer patients with bone metastasis. Clin Respir J. 2021;15(2):225–231. 2020/10/11. doi: 10.1111/crj.13288.
   PubMed Web of Science ®Google Scholar
• Kim JS, Choi M, Kim SH, et al. Systemic inflammation response index correlates with survival and predicts oncological outcome of resected pancreatic cancer following neoadjuvant chemotherapy. Pancreatology. 2022;22(7):987–993. 2022/09/06. doi: 10.1016/j.pan.2022.08.009.
   PubMed Web of Science ®Google Scholar
• Qi Q, Zhuang L, Shen Y, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016;122(14):2158–2167. 2016/05/07. doi: 10.1002/cncr.30057.
   PubMed Web of Science ®Google Scholar
• Jin YN, Liu BQ, Peng KW, et al. The prognostic value of adding systemic inflammation response index to Epstein-Barr virus DNA in childhood nasopharyngeal carcinoma: a real-world study. Head Neck. 2022;44(6):1404–1413. 2022/04/05. doi: 10.1002/hed.27033.
   PubMed Web of Science ®Google Scholar
• Cai H, Chen Y, Zhang Q, et al. High preoperative CEA and systemic inflammation response index (C-SIRI) predict unfavorable survival of resectable colorectal cancer. World J Surg Oncol. 2023;21(1):178. 2023/06/09. doi: 10.1186/s12957-023-03056-z.
   PubMed Web of Science ®Google Scholar
• Feng J, Wang Q. Correlation of systemic immune-inflammatory response index with clinical data in patients with malignant ovarian tumor. Am J Transl Res. 2023;15:3309–3317. 2023/06/12.
   PubMed Web of Science ®Google Scholar
• Yazici H, Yegen SC. Is systemic inflammatory response index (SIRI) a reliable tool for prognosis of gastric cancer patients without neoadjuvant therapy? Cureus. 2023;15(3):e36597. 2023/04/25. doi: 10.7759/cureus.36597.
   PubMed Web of Science ®Google Scholar
• Ye K, Xiao M, Li Z, et al. Preoperative systemic inflammation response index is an independent prognostic marker for BCG immunotherapy in patients with non-muscle-invasive bladder cancer. Cancer Med. 2023;12(4):4206–4217. 2022/10/11. doi: 10.1002/cam4.5284.
   PubMed Web of Science ®Google Scholar
• Hua X, Long ZQ, Huang X, et al. The preoperative systemic inflammation response index (SIRI) independently predicts survival in postmenopausal women with breast cancer. Curr Probl Cancer. 2020;44(4):100560. 2020/03/04. doi: 10.1016/j.currproblcancer.2020.100560.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhou Y, Xia S, et al. Prognostic value of the systemic inflammation response index (SIRI) before and after surgery in operable breast cancer patients. Cancer Biomark. 2020;28(4):537–547. 2020/06/23. doi: 10.3233/cbm-201682.
   PubMed Web of Science ®Google Scholar
• He Q, Li JY, Ren QL. Efficacy of neoadjuvant single or dual anti-HER-2 therapy combined with chemotherapy in patients with HER-2-positive breast cancer: a Single-Center retrospective study. Asian Pac J Cancer Prev. 2021;22(5):1467–1475. 2021/05/29. doi: 10.31557/apjcp.2021.22.5.1467.
   PubMedGoogle Scholar
• Jiang C, Zhang S, Qiao K, et al. The pretreatment systemic inflammation response index as a useful prognostic factor is better than lymphocyte to monocyte ratio in breast cancer patients receiving neoadjuvant chemotherapy. Clin Breast Cancer. 2022;22(5):424–438. 2022/04/17. doi: 10.1016/j.clbc.2022.03.003.
   PubMed Web of Science ®Google Scholar
• Zhu M, Chen L, Kong X, et al. The systemic inflammation response index as an independent predictor of survival in breast cancer patients: a retrospective study. Front Mol Biosci. 2022;9:856064. 2022/03/18. doi: 10.3389/fmolb.2022.856064.
   PubMed Web of Science ®Google Scholar
• Yamanouchi K, Maeda S. The efficacy of inflammatory and immune markers for predicting the prognosis of patients with stage IV breast cancer. Acta Med Okayama. 2023;77(1):37–43. 2023/02/28. doi: 10.18926/amo/64360.
   PubMed Web of Science ®Google Scholar
• Huang W, Xiong Z, Zhong W, et al. Development of a nomogram for predicting survival of breast cancer patients with neoadjuvant chemotherapy: a dynamic analysis for systemic inflammation response index. Gland Surg. 2023;12(11):1459–1474. 2023/12/18. doi: 10.21037/gs-23-226.
   PubMed Web of Science ®Google Scholar
• Wu HY, Lin CY, Tzeng YD, et al. Preoperative systemic inflammation response index: clinicopathologic predictor of pathological complete response in HER2-positive breast cancer patients receiving neoadjuvant systemic therapy. J Chin Med Assoc. 2024;87(2):226–235. 2023/12/14. doi: 10.1097/jcma.0000000000001034.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269, W64. W264. doi: 10.7326/0003-4819-151-4-200908180-00135.
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605. doi: 10.1007/s10654-010-9491-z.
   PubMed Web of Science ®Google Scholar
• Hagerling C, Werb Z. Neutrophils: critical components in experimental animal models of cancer. Semin Immunol. 2016;28(2):197–204. 2016/03/16. doi: 10.1016/j.smim.2016.02.003.
   PubMed Web of Science ®Google Scholar
• Mayer C, Darb-Esfahani S, Meyer AS, et al. Neutrophil granulocytes in ovarian Cancer - Induction of Epithelial-To-Mesenchymal-Transition and tumor cell migration. J Cancer. 2016;7(5):546–554. 2016/04/08. doi: 10.7150/jca.14169.
   PubMed Web of Science ®Google Scholar
• Xiong S, Dong L, Cheng L. Neutrophils in cancer carcinogenesis and metastasis. J Hematol Oncol. 2021;14(1):173. 2021/10/23. doi: 10.1186/s13045-021-01187-y.
   PubMed Web of Science ®Google Scholar
• Chanmee T, Ontong P, Konno K, et al. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel). 2014;6(3):1670–1690. 2014/08/16. doi: 10.3390/cancers6031670.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137–148. 2004/08/17. doi: 10.1016/j.immuni.2004.07.017.
   PubMed Web of Science ®Google Scholar
• Mahmoud SM, Paish EC, Powe DG, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949–1955. 2011/04/13. doi: 10.1200/jco.2010.30.5037.
   PubMed Web of Science ®Google Scholar
• Wang L, Qin X, Zhang Y, et al. The prognostic predictive value of systemic immune index and systemic inflammatory response index in nasopharyngeal carcinoma: a systematic review and meta-analysis. Front Oncol. 2023;13:1006233. 2023/02/24. doi: 10.3389/fonc.2023.1006233.
   PubMed Web of Science ®Google Scholar
• Liang XW, Liu B, Yu HJ, et al. Prognostic significance of the systemic inflammation response index in gastrointestinal malignancy patients: a pooled analysis of 10,091 participants. Future Oncol. 2023;19(29):1961–1972. 2023/10/06. doi: 10.2217/fon-2023-0545.
   PubMed Web of Science ®Google Scholar
• Jarmuzek P, Kozlowska K, Defort P, et al. Prognostic values of systemic inflammatory immunological markers in glioblastoma: a systematic review and meta-analysis. Cancers (Basel). 2023;15(13):3339. 2023/07/14. doi: 10.3390/cancers15133339.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Su S, You W, et al. Systemic inflammation response index as a prognostic marker in cancer ­patients: a systematic review and meta-analysis of 38 cohorts. Dose Response. 2021;19(4):2022/01/07. doi: 10.1177/15593258211064744.
   Web of Science ®Google Scholar